News & Views
Support From NanoKTN Helps Formation of University Spin-Out
Apr 17 2012 Read 1007 Times
The Nanotechnology Knowledge Transfer Network one of the UK’s primary knowledge-based networks for Micro and Nanotechnologies, is pleased to announce that member Nanomerics, a spin-out from UCL School of Pharmacy, is taking its patented nano-enabled therapeutic technology to international markets. Presenting at NanoKTN events
and attending NanoKTN’s international missions, has enabled Nanomerics to spin-out and find commercial partners for its Peptide Pill therapeutics products and secure funding to further develop its pain therapeutic technologies.
Founding scientist at Nanomerics, Professor Ijeoma Uchegbu first presented UCL School of Pharmacy’s pain therapeutics technology at the NanoKTN’s annual Nano4Life event, which discusses the convergence of nanotechnology with the life science industry and used the event to demonstrate how nanotechnology can be exploited to produce better pain therapies.
Following the successful Nano4Life event, Professor Uchegbu was invited as part of the NanoKTN delegation to the BioPharm America conference in Boston, USA. Professor Uchegbu comments, “The interest at the Nano4Life event and the inspiration and support given by the NanoKTN, gave us the push to register the company and spin out the technology projects into Nanomerics and take this vehicle to BioPharm America in search of potential collaboration partners and funding for further product development.”
At BioPharm America, Nanomerics met with a number of interested parties, resulting in a formal agreement with a US drug company already working in the pain market and secured further funding via an award from the Technology Strategy Board/EPRSC to look into developing its own pain product, a nanotechnology enabled Peptide Pill called METDoloron. METDoloron is an oral analgesic based on an endogenous peptide and allows treatment of severe chronic pain as a 'Peptide Pill' using Nanomerics' MET technology.
Professor Uchegbu explained, “Working with the NanoKTN has provided us with unique networking opportunities and a platform to find collaboration partners to market our nanotechnology pain solutions to a global audience and to develop new pain therapeutic solutions. Collaborating with US partners on projects, we hope that a formulation will progress into clinical trials.”
Andreas Schätzlein, Nanomerics co-founder and CEO said, “Early engagement with industry has been essential in shaping the development of our technologies from the start. However, accessing the global market with the help of NanoKTN and others has been essential in finding the right partners to take the technology forward in a product focussed fashion.”
“Nanomerics is an excellent example of a UK company taking a successful technology developed at UK universities to a global market. We are delighted to have played a part in the success of Nanomerics and look forward to continuing to support the company as it grows.” added Dr Mike Fisher, Healthcare & Life Sciences Theme Manager at the
Further information about the NanoKTN can be found at www.nanoktn.com or by emailing email@example.com.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...
View all digital editions
Jan 27 2020 Dubai, UAE
Jan 29 2020 Tokyo, Japan
Feb 03 2020 Dubai, UAE
Feb 12 2020 Tokyo, Japan
Feb 17 2020 Berlin, Germany